Published in AIDS Weekly, January 10th, 2005
The findings are from study APV30005, a rollover study that enrolled 211 patients who completed 48 weeks of treatment in the SOLO study (APV30002) with Lexiva/r QD in combination with abacavir and lamivudine twice daily.
Lexiva was co-discovered by GlaxoSmithKline (GSK) and Vertex Pharmaceuticals (VRTX). It is indicated for the treatment of HIV infection in adults in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.